Nocturia Market

Market Overview:

The 7 major nocturia markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.93% during 2024-2034.

The nocturia market has been comprehensively analyzed in IMARC's new report titled "Nocturia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nocturia is a medical condition characterized by the need to wake up one or more times during the night to urinate. It typically disrupts the normal sleep cycle and affects the quality of life. The common symptoms include a strong urge to urinate, difficulty initiating urination, pain or discomfort while urinating, a feeling of incomplete bladder emptying, etc. In addition to physical indications, nocturia can also have a negative impact on an individual's mental health and overall well-being, leading to feelings of anxiety, depression, and social isolation. The diagnosis of this ailment usually requires a review of medical history, along with urine culture, urinalysis, and blood tests. The healthcare professional may ask about the patient's urination patterns, sleep habits, and other relevant symptoms to help identify potential underlying causes of nocturia. Several diagnostic procedures, including urine tests to look for signs of infection or abnormalities, blood tests to check kidney function, and imaging studies like ultrasound and MRI to assess the bladder and other organs, are also performed. Additionally, the healthcare professional may perform urodynamic analyses to examine the lower urinary tract stores and urine release among patients.

The increasing prevalence of bladder obstruction disorder and urinary tract inflammation, which impair bladder capacity and increase urine frequency, is primarily driving the nocturia market. In addition to this, the rising incidence of excess urine production at night owing to several risk factors, such as sleep disorders like sleep apnea, high intake of fluids, poor kidney functions, etc., is also propelling the market growth. Furthermore, the inflating adoption of effective medications, including Beta-3 adrenoceptor agonists and anticholinergic drugs, to help reduce bladder spasms and lessen the symptoms of an overactive bladder is acting as another significant growth-inducing factor. Apart from this, the escalating application of uroflowmetry for identifying any blockages or abnormalities in the urinary tract that may be contributing to nocturia is further creating a positive outlook for the market. Moreover, the widespread demand for sacral nerve stimulation, which can treat high urinary incontinence and frequency, is also augmenting the market growth. This method uses a minimally invasive advanced technique that involves implanting a tiny device in the buttock or abdomen to stimulate the sacral nerves and help reduce disease severity. Additionally, the emerging popularity of combined therapy, including a combination of pharmacological medications and lifestyle changes, such as regulating beverage consumption, limiting caffeine and alcohol intake at night, etc., is further expected to drive the nocturia market in the coming years.   

IMARC Group's new report provides an exhaustive analysis of the nocturia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nocturia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nocturia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the nocturia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the nocturia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current nocturia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the nocturia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the nocturia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the nocturia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of nocturia across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of nocturia by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of nocturia by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with nocturia across the seven major markets?
• What is the size of the nocturia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of nocturia?
• What will be the growth rate of patients across the seven major markets?
   

Nocturia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for nocturia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nocturia market?
• What are the key regulatory events related to the nocturia market?
• What is the structure of clinical trial landscape by status related to the nocturia market?
• What is the structure of clinical trial landscape by phase related to the nocturia market?
• What is the structure of clinical trial landscape by route of administration related to the nocturia market?